Work

Population pharmacokinetics of tofacitinib in patients with active ankylosing spondylitis

Year: 2025

Type: article

Abstract: OBJECTIVE: To characterize tofacitinib pharmacokinetics (PK) in patients with active ankylosing spondylitis (AS) and estimate the effects of covariates on variability of PK parameters. MATERIALS AND METHODS: ). Covariates evaluated: baseline age, sex, race, creatinine clearance (BCCL), and C-reactive protein for CL/F; baseline age/body weight for V/F. RESULTS: ratios indicated no major differences in tofacitinib exposure over the range of baseline age/body weight studied, and sex/race. CONCLUSION: Tofacitinib does not require dose adjustment/restriction for age, body weight, sex, or race based on the differences (< 20%) in exposure relative to a reference patient with AS. The tofacitinib CL/F and BCCL relationship was consistent with known contribution of renal excretion to total tofacitinib clearance.

Source: International Journal of Clinical Pharmacology and Therapeutics

DOI: 10.5414/cp204781

Authors: Shinichi Tsuchiwata, Akiyuki Suzuki, Qiang Wang, Keith Kanik, Lara Fallon, Sujatha Menon

Language: English

Topic: Spondyloarthritis Studies and Treatments

Subfield: Rheumatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W4417104675

FWCI:

Cites:

Cited by:

Related to: